检索结果-南通市图书馆

Adjuvant tamoxifen switched to exemestane treatment in postmenopausal women with estrogen receptor-positive early breast cancer:A pragmatic,multicenter,and prospective clinical trial in China

引用

Chinese Journal of cancer Research 2022年第6期34卷 592-600页

作者： Binghe Xu Huiping Li Zefei Jiang Lin Gu Jinhai Tang Hui Xie Yueyin Pan Yunjiang Liu Shude Cui Xiaojia Wang Li Cai Yiqiong Zhang Huadong Zhao Zhimin Shao Department of Medical Oncology National Cancer Center/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing) Department of Breast OncologyPeking University Cancer Hospital&InstituteBeijing 100142China Department of breast cancer the Fifth Medical Center of Chinese PLA General HospitalBeijing 100071China Department of breast cancer Tianjin Cancer Institute and HospitalTianjin 300060China Department of breast cancer Jiangsu Provincial HospitalNanjing 210029China Department of breast cancer the First Affliated Hospital of China University of Science and TechnologyHefei 230001China Department of breast cancer the Fourth Hospital of Hebei Medical UniversityShijiazhuang 050011China Department of breast cancer Henan Cancer HospitalZhengzhou 450008China Department of breast cancer Zhejiang Cancer HospitalHangzhou 310012China Department of breast cancer Harbin Medical University Cancer HospitalHarbin 150081China Department of Clinical Development Pfizer(China)R&D Co.LtdShanghai 201203China Department of Statistics Pfizer(China)R&D Co.LtdShanghai 201203China Department of breast Surgery Shanghai Cancer Center/Cancer InstituteShanghai Medical CollegeFudan UniversityShanghai 200032China

Objective:This post-approval safety study assessed the efficacy and safety of exemestane after 2-3 years of tamoxifen treatment among postmenopausal women with estrogen receptor-positive(ER+)early breast cancer in ***:Enrolled patients had received 2-3 years of tamoxifen and were then switched to exemestane for completion of 5 consecutive years of adjuvant endocrine *** primary endpoint was the time from enrollment to the first occurrence of locoregional/distant recurrence of the primary breast cancer,appearance of a second primary or contralateral breast cancer,or death due to any *** endpoints included the proportion of patients experiencing each event,incidence rate per annum,relationships between human epidermal growth factor receptor 2 status and time to event,and relationship between disease history variables and time to ***:Overall,558 patients were included in the full analysis set:397(71.1%)completed the study,20experienced an event,and 141 discontinued[47 owing to an adverse event(AE);37 no longer willing to participate].Median duration of treatment was 29.5(range,0.1-57.7)*** time to event was not *** survival probability at 36 months was 91.4%(95%CI,87.7%-95.1%).The event incidence over the total exposure time of exemestane therapy was 3.5 events/100 person-years(20/565).Multivariate analysis showed an association between tumor,lymph node,and metastasis stage at initial diagnosis and time to event[hazard ratio:1.532(95%CI,1.129-2.080);P=0.006].Most AEs were grade 1 or 2 in severity,with arthralgia(7.7%)being the most common treatment-related ***:This study supports the efficacy and safety of exemestane in postmenopausal Chinese women with ER+breast cancer previously treated with adjuvant tamoxifen for 2-3 *** new safety signals were identified in the Chinese population.

关键词： Chinese early breast cancer exemestane tamoxifen postmenopausal women estrogen receptor-positive

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

The use of liquid biopsy in early breast cancer:clinical evidence and future perspectives

引用

Journal of cancer Metastasis and Treatment 2021年第1期7卷 33-48页

作者： Paolo D’Amico Carla Corvaja Lorenzo Gerratana Carolina Reduzzi Giuseppe Curigliano Massimo Cristofanilli Division of Hematology and Oncology Department of MedicineNorthwestern University Feinberg School of MedicineChicagoIL 60611USA Division of early Drug Development for Innovative Therapies IEOEuropean Institute of Oncology IRCCSMilan 20132Italy Department of Oncology and Hemato-Oncology University of MilanoMilan 20122Italy Department of Oncology ASUFCUniversity Hospital of UdineUdine 33100Italy Department of Medicine University of UdineUdine 33100Italy Department of Medical Oncology Centro di Riferimento Oncologico(CRO)IRCCSPordenone 33081Italy

Liquid biopsy,including both circulating tumor cells and circulating tumor DNA,is gaining momentum as a diagnostic modality adopted in the clinical management of breast *** studies testing several technologies demonstrated clinical validity and,in some cases,achieved the United States Food and Drug Administration *** initial testing and clinical application of liquid biopsy focused primarily on the diagnosis,while molecular characterization and monitoring of metastatic disease,with larger data from prospective studies,came in the last two *** its role in metastatic setting is thus widely recognized,the current evidence does not provide support for the routine clinical use of liquid biopsy methods for the earlier stage of this *** the relevance of early detection,characterization,and management of breast cancer in the early-stage,this clinical setting is the most suitable to increase the chances for effective treatment selection and improved prognosis,and a better understanding of the main application of liquid biopsy tools in the earlier stage of breast cancer is therefore *** aim of this review is to provide an overview of the clinical evidence and subsequent potential applications of liquid biopsy in early breast cancer,identifying the main existing caveats and the possible future scenarios.

关键词： Liquid biopsy early breast cancer circulating tumor cells circulating tumor DNA clinical trials screening early detection minimal residual disease

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Clinical Observation of breast Conserving Surgery and Modified Radical Mastectomy in the Treatment of early breast cancer

引用

Advances in Modern Oncology Research 2019年第6期5卷 20-22页

作者： NFabio Puglisi Amy Stem Marie Valero Department of Pharmacology and Toxicology Faculty of PharmacyCairo UniversityCairoEgypt Department of Radiation Oncology Technical University of Munich(TUM)Germany Division of Radiation Oncology Allegheny Health Network Cancer InstitutePittsburghPAUSA

The purpose of the study was to compare the clinical efficacy of breast conserving surgery and modified radical mastectomy in the treatment of early breast ***,the clinical data of 74 patients with early breast cancer treated in our hospital from June 2015 to June 2016 were retrospectively *** them,37 patients treated with breast-conserving surgery were set as the study group,and 37 patients treated with modified radical surgery were set as the control group,and the therapeutic effects of the two groups were *** results showed that compared with the control group,the incision length,intraoperative blood loss,operation time and hospital stay time were better in the study group,and the excellent and good rate of postoperative breast beauty was higher,with statistically significant differences(P0.05).Therefore,breast-conserving surgery and modified radical surgery have better efficacy in the treatment of early breast cancer,but breast-conserving surgery has more advantages,such as smaller incision,less intraoperative blood loss,shorter operative time and hospital stay,and better postoperative aesthetic effect,which can be used as the first choice for early breast cancer.

关键词： early breast cancer Maintain breast augmentation Improved radical resection Clinical curative effect

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

The 10-Year Local Recurrence and Partial breast Radiotherapy for early breast cancer Treated by Conservative Surgery

引用

Chinese Journal of Clinical Oncology 2006年第6期3卷 428-432,441页

作者： Zhizhen Wang Ruiying Li Department of Radiotherapy Tianjin Medical University Cancer Institute ＆ Hospital Tianjin 300060 China

To study the local recurrence and the role of whole breast radiotherapy for early breast cancer treated by conservative surgery. METHODS From April 1990 to December 2000, 49 patients with early primary breast cancer were treated by conservative surgery in our hospital. The cases were comprised of Stage 0, 1; Stage Ⅰ, 31; and Stage Ⅱa, 17. Forty cases underwent quadrantectomy plus axillary lymph node dissection, and the other 9 cases had lumpectomy alone. Irradiation, which was received by 39 patients, was administered by using low tangential half fields with 6 MV X-ray to decrease the pulmonary irradiative volume. The dose to the whole breast was 45 Gy/22 ～23f/4.5W, then a 15 Gy boost dose was delivered to the tumor bed by an electron beam. The other patients underwent an irradiated regional field according to postoperative pathology. RESULTS All patients were followed-up for 10 years or more. The 10- year local recurrence rates, distant metastasis rates and survival rates were 6.1%, 4.1% and 98.0% respectively. All of the 3 patients who had a local recurrence had infiltrative carcinomas and negative lymph nodes. The 10-year local recurrence rate was higher （2.6% vs. 20.0%） with nonpostoperative whole breast radootherapy, but the statistical difference was not marked because of the low number of cases. All of the recurrent lesions localized within 3 cm of the primary lesion. CONCLUSION Original recurrence of the tumor was the main type of local recurrence. Radiotherapy after conservative surgery is very essential. After conservative surgery it is feasible that irradiation can be delivered alone to the neighboring region of the tumor bed. Partial breast radiotherapy can substitute for whole breast radiotherapy.

关键词： early breast cancer conservative surgery partial breast mdiolherapy local recurrence original recurrence whole breast mdiolhempy.

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Relationship between serum HER2 extracellular domain levels, tissue HER2 expression, and clinico-pathological parameters in early stage breast cancer

引用

Chinese Medical Journal 2012年第22期125卷 4104-4110页

作者： MA Li YANG Hong-ying HAN Xiao-hong LI Jia WANG Fang ZHANG Chun-ling YAO Jia-rui SHI Yuan-kai Chinese Acad Med Sci Canc Inst Hosp Dept Med Oncol Beijing 100021 Peoples R China Chinese Acad Med Sci Canc Inst Hosp Dept Pathol Beijing 100021 Peoples R China Chinese Acad Med Sci Canc Inst Hosp Dept Lab Med Beijing 100021 Peoples R China Peking Union Med Coll Beijing 100021 Peoples R China

Background Measurement of human epidermal growth factor receptor 2 （HER2） protein in the serum of metastatic breast cancer patients has previously been reported, but there are no consistent data to support the clinical utility of serum HER2 extracellular domain for patients with early stage breast cancer. We aimed to evaluate the correlation between serum extracellular domain levels and tissue HER2 expression, and analyzed their relationship with clinico-pathological parameters in patients with early stage disease. Methods A prospective study was conducted on 232 breast cancer patients with stage I-III prior to treatment. Preoperative serum samples were measured by enzyme-linked immunosorbent assay. Tissue HER2 status was analyzed by immunohistochemistry and fluorescence in situ hybridization assays. Results The median serum extracellular domain concentration was 6.8 ng/ml. The best diagnostic cut-off value was 7.4 ng/ml, with 62.9% sensitivity and 85.3% specificity. High serum extracellular domain levels were reported in 89 patients （38.3%）, and HER2-positive expression was observed in 77 patients （33.2%）. Multivariate analysis showed that elevated serum extracellular domain correlated with postmenopausal status （P 〈0.001）, high histological grade （P 〈0.001）, negativity of both estrogen （P=0.012） and progesterone receptors （P 〈0.001）, and high levels of carcinoembryonic antigen 153 （P=-0.048）. Conclusions We recommend that 7.4 ng/ml should be used as the cut-off value when evaluating serum extracellular domain levels in early stage of breast cancer. Patients with high serum extracellular domain levels have a certain clinico- pathological characteristics, may provide a basis for clinical practice.

关键词： early breast cancer enzyme-linked immunosorbent assay fluorescence in situ hybridization assay human epidermal growth factor receptor 2 immunohistochemistry

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Two Modified Surgical Procedures for Treating early Stage breast cancer in China

引用

Journal of Huazhong University of Science and Technology(Medical Sciences) 2014年第6期34卷 917-920页

作者：邓裴吴乐昊任玉萍吴毅平 Department of Plastic and Reconstructive Surgery Tongji Hospital Tongji Medical College Huazhong University of Science and Technology

Conventional pedicled-flap based surgeries in treating breast cancer have their limitations. New surgical regimens are yet to be explored, which will follow the oncological principle of being “to- tal tumor free”, whilst fit into the unique characteristics of China＇s own medical system as well as pa- tients＇ demand. From 2007 to 2013, 143 patients with early stage breast cancer were included in the study, with the average age of 46.1 years. Fifty-three patients were subjected to modified breast con- serving surgery （MBCS）＋latissimus dorsi （LD） flap reconstruction, 41 to skin sparing mastectomy （SSM）＋implant＋LD flap reconstruction, 29 to MBCS＋distal transverse rectus abdominis myocutaneous （DTRAM） flap reconstruction, and 20 to SSM＋DTRAM flap reconstruction. The results showed that out of the 143 patients, there was no graft loss. Minor complications included 4 cases of fat liquefaction, and 6 cases of seratoma, which all resolved after conservative treatment. Five patients had visible protu- berance in the abdomen, but not leading to any gastrointestinal symptoms. The reconstructed breasts all presented good shape. 96.7% of the patients were satisfied with the outcome. The follow-up period var- ied from 6 months to 60 months, and only one patient died from tumor metastasis in the brain. No local recurrence occurred. It was concluded that these two modified pedicled-flap surgeries are readily practi- cal, and aesthetically satisfactory, with high applicability in China. They do not compromise the on- cological outcomes, but also are well-accepted by Chinese patients.

关键词： early breast cancer breast conserving surgery modified transverse rectus abdominismyocutaneous flap reconstruction

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Assessing the Clinical Efficacy and Effectiveness of Sentinel Lymph Node Biopsy Combined with breast-Conserving Surgery for early-Stage breast cancer

引用

Proceedings of Anticancer Research 2023年第6期7卷 72-77页

作者： Jiehou Fan The Second Department of breast Surgery Dezhou Second People’s HospitalDezhou 253000Shandong ProvinceChina

Objective:To analyze the impact of sentinel lymph node biopsy(SLNB)combined with breast-conserving surgery in the clinical treatment of early-stage breast ***:80 patients with early-stage breast cancer admitted to the Second Department of breast Surgery at Dezhou Second People’s Hospital from September 2020 to September 2022 were selected and randomly divided into a control group and an observation group using the random number table method,with 40 cases in each *** control group underwent a modified radical mastectomy,while the observation group underwent SLNB combined with breast-conserving *** surgical efficacy and prognosis between the two groups were ***:The observation group exhibited shorter operation,hospitalization,and extubation times,as well as less intraoperative blood loss and drainage volume,all of which were significantly better than those in the control group(Pbreast cosmetology and quality of life,with lower complication incidence,significantly outperforming the control group(P0.05).Conclusion:The combination of SLNB and breast-conserving surgery proves highly effective for patients with early-stage breast cancer,presenting fewer complications and enhancing both breast cosmetic outcomes and quality of life.

关键词： early breast cancer Sentinel lymph node biopsy breast-conserving surgery Clinical efficacy

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Prognostic value of the 21-gene recurrence score in ER-positive,HER2-negative,node-positive breast cancer was similar in nodenegative diseases:a single-center study of 800 patients

引用

Frontiers of Medicine 2021年第4期15卷 621-628页

作者： Jiayi Wu Weiqi Gao Xiaosong Chen Chunxiao Fei Lin Lin Weiguo Chen Ou Huang Siji Zhu Jianrong He Yafen Li Li Zhu Kunwei Shen Comprehensive breast Health Center Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of MedicineShanghai 200025China

Multi-gene assays have emerged as crucial tools for risk stratification in early-stage breast *** study aimed to evaluate the prognostic significance of the 21-gene recurrence score(RS)in Chinese patients with pN0-l,estrogen receptor-positive(ER+),human epidermal growth factor receptor 2-negative(HER2)breast *** 800 patients recruited between 2009 and 2016,the median RS was 24(0-69),with 27.4%,46.8%,and 25.9%patients classified into low-,intermediate-,and high-risk *** regression analysis demonstrated that the high-risk category was associated with significantly higher odds of invasive disease-free survival(IDFS)and distant disease-free survival(DDFS)events compared with the low-risk category(IDFS:HR=2.450,95%Cl 1.017-5.902,P=0.046;DDFS:HR=2.829,95%Cl 1.013-7.901,P=0.047).No significant association between RS category and overall survival(OS)was found(intermediate ***:HR=1.244,95%Cl 0.292-5.297,P=0.768;high ***:HR=2.933,95%Cl 0.759-11.327,P=0.119).RS,as a continuous variable,was a highly significant predictor for IDFS(HR=1.028,95%Cl 1.010-1.047,P=0.002),DDFS(HR=1.030,95%Cl 1.010-1.051,P=0.003),and OS(HR=1.034,95%Cl 1.007-1.063,P=0.014).Our findings suggested that RS may predict IDFS in Chinese patients with ER+/HER2 breast cancer with NO or N1 disease.

关键词： early breast cancer 21-gene assay recurrence score prognosis

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

MICROW AVE-INDUCED THERMOA COUSTIC IMAGING FOR early breast CA NCER DETECTION

引用

Journal of Innovative Optical Health Sciences 2013年第1期6卷 38-43页

作者： ZHONG JI YONG FU SIHUA YANG MOE Key Laboratory of Laser Life Science and Institute of Laser Life Science South China Normal University Guangzhou 510631P.R.China

Microwave induced thermoacoustic tomography(TAT)is a noninvasive,nonionizing modality based on the inherent differences in microwave absorpt ion of malignant breast tissues and normal adipose dominated breast *** this paper,a TAT system based on multielement acquisition system was built to receive *** from different layers in the sample were composed into a three-dimensional(3D)*** on the 3D volume,inherent differences in microw ave absorption bet ween different biological tisues can be converted into structure *** experimental results of some minicked and human tumors indicate that TAT may potentially be used to detect early-stage breast cancers with high contrast.

关键词： early breast cancer microwave induced thermoacoustic tomography dielectric properties

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Circulating tumor cells and drug history in primary breast cancer patients

引用

cancer Drug Resistance 2020年第1期3卷 98-109页

作者： Silvia Jurisova Marián Karaba Gabriel Minarik Juraj Benca Tatiana Sedlackova Daniela Manasova Katarina Kalavska Daniel Pindak Jozef Mardiak Michal Mego nd Department of Oncology Faculty of MedicineComenius UniversityBratislava 83310Slovakia National cancer Institute Bratislava 83310Slovakia Slovak Medical University Bratislava 83101Slovakia Institute of Molecular Biomedicine Faculty of MedicineComenius UniversityBratislava 83172Slovakia Department of Medicine St.Elizabeth UniversityBratislava 81250Slovakia

Aim:Different types of chronic medication may affect breast cancer *** tumor cells(CTCs)play an important role in cancer metastasis *** is no evidence of how chronic medication affects CTCs and breast cancer *** aim of this study was to evaluate association between chronic medication and CTCs in patients with primary breast ***:This study involved 414 patients with stage I-III primary breast *** drug history was collected from patients’medical records and included all drugs that were prescribed for patients over at least the last 6 months prior to CTCs *** were detected using a quantitative real-time polymerase chain reaction(qRT-PCR)-based method at the time of breast ***:There was no association between CTCs,including their different subpopulations and chronic *** medication using angiotensin-converting-enzyme inhibitors(ACEi),metformin,and insulin were associated with inferior disease-free survival(HR=0.49,95%CI 0.26-0.94,P=0.007 for ACEi;HR=0.27,95%CI 0.08-0.91,Pbreast cancer ***,administration of ACEi,metformin,and/or insulin could negatively affect prognosis of patients with CTC_EMT.

关键词： Circulating tumor cells chronic medication epithelial-to-mesenchymal transition early breast cancer

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：